Form 4: Gossamer Bio Director Receives Stock Option Grant

Director Daniel Thomas O was granted 115,000 stock options in Gossamer Bio, Inc. as part of the company's non-employee director compensation program.

Summary

• Director Daniel Thomas O received a grant of 115,000 stock options on June 4, 2026.
• The options have an exercise price of $0.178 per share.
• The grant is part of the standard Non-Employee Director Compensation Program.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on continued service of the director to satisfy vesting requirements.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service.

Management Comments

• The award was made pursuant to the company's established Non-Employee Director Compensation Program.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant structure follows standard industry practices for small-cap biotech firms.
• Vesting schedules tied to annual meetings or one-year anniversaries are consistent with typical board compensation policies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on the earlier of June 4, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, Insider Trading, Stock Options, Director Compensation